...

Expert Analysis

First-Line Therapy and Switch Strategies

Source: CCO Official Conference Coverage of the 2006 International AIDS Conference

First-Line Therapy and Switch Strategies


Faculty:

David A. Cooper, MD, DScJoel E. Gallant, MD, MPHKimberly Y. Smith, MD, MPH
  • David A. Cooper, MD, DSc
  • Joel E. Gallant, MD, MPH
  • Kimberly Y. Smith, MD, MPH

CREDIT INFORMATION

Release Date: September 29, 2006

Expiration Date: September 28, 2007


Physicians: maximum of 1.5 AMA PRA Category 1 Credits

Registered Nurses: 1.6 Nursing contact hours

Pharmacists: 1.4 contact hours (0.14 CEUs)

Status: The activity is not currently available for credit.


Begin the Expert Analysis

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss recent data comparing the outcomes of different first-line therapy regimens using FDA-approved agents
  • Describe data from a study of the integrase inhibitor MK-0518 in treatment-naive patients
  • Review the latest studies describing the outcomes of therapy with boosted-PI monotherapy in treatment-naive patients or those with virologic suppression on a standard HAART regimen
  • Recount findings from recent analyses of studies of treatment interruption strategies

Topics covered include:

  • ACTG 5142: Comparison of Efavirenz- vs Lopinavir/Ritonavir-Based Regimens
  • CPCRA 058 FIRST: Comparison of NNRTI-Based vs PI-Based vs NNRTI/PI-Based Regimens
  • KLEAN Study: Comparison of Lopinavir/Ritonavir vs Fosamprenavir/Ritonavir Regimens
  • ACTG 5095: Comparison of 3-Drug vs 4-Drug Regimens
  • Comparison of Investigational Integrase Inhibitor MK-0518 With Efavirenz
  • Study 934: Comparison of Zidovudine/Lamivudine vs Tenofovir/Emtricitabine Regimens
  • Update of IAS-USA Guidelines
  • Studies Assessing Lopinavir/Ritonavir Monotherapy
  • SWAN: Switch From Lopinavir/Ritonavir to Atazanavir-Based Therapy
  • SMART Analyses: Causes of Increased Risk Associated With Treatment Interruption
  • DART: Failure of Fixed-Cycle Treatment Interruptions


Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.

CCO Resources

CCO Expert Recap of data from the 2006 International AIDS Conference